PHC: the future of oncology drug development
- PDF / 82,480 Bytes
- 1 Pages / 595.28 x 793.7 pts Page_size
- 6 Downloads / 293 Views
MEETING ABSTRACT
Open Access
PHC: the future of oncology drug development Yihong Yao From 2012 Sino-American Symposium on Clinical and Translational Medicine (SAS-CTM) Shanghai, China. 27-29 June 2012 Background Major investments in basic science have created an opportunity for significant progress in clinical medicine. Molecularly targeted therapies aim to interfere with molecular mechanisms, selectively involved in carcinogenesis and tumor growth in order to optimize the efficacy and minimize the side effects of anticancer treatment. Moving from concept to clinical use requires basic, translational, and regulatory science. Today, about 10% of labels for FDAapproved drugs contain pharmacogenomic information — a substantial increase since the 1990s but hardly the limit of the possibilities for this aspect of personalized medicine.
especially for cancer patients with significant unmet need. Acknowledgements Koustubh Ranade, Jiaqi Huang, and Brandon Higgs contribute to the abstract and work discussed in the presentation. Published: 17 October 2012
doi:10.1186/1479-5876-10-S2-A12 Cite this article as: Yao: PHC: the future of oncology drug development. Journal of Translational Medicine 2012 10(Suppl 2):A12.
Materials and methods There has been an explosion in the number of promising markers but significant gap exists in independent analysis of the validity of the tests used to identify them in biologic specimens. The success of personalized medicine depends on having accurate diagnostic tests that identify patients who can benefit from targeted therapies. Results In this presentation, case examples of how MedImmune/ Astrazeneca incorporate personalized medicine/molecular diagnostic into clinical development to ensure targeted therapeutics successfully reach the right patient population will be discussed. These examples will illustrate how close cooperation among basic science, translational, clinical and regulatory departments together with partnerships with diagnostic companies are needed to reduce the dream of personalized healthcare into practice. Conclusions By identifying the right patient population at the outset of the clinical development process we hope to improve the probability of success of oncology clinical trials, which is an urgent requirement across the industry, but Correspondence: [email protected] Translational Sciences, MedImmune, LLC, Gaithersburg, MD, 20878, USA
Submit your next manuscript to BioMed Central and take full advantage of: • Convenient online submission • Thorough peer review • No space constraints or color figure charges • Immediate publication on acceptance • Inclusion in PubMed, CAS, Scopus and Google Scholar • Research which is freely available for redistribution Submit your manuscript at www.biomedcentral.com/submit
© 2012 Yao; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any me
Data Loading...
